Pfizer Inc. (NYSE:PFE) Morgan Stanley 20th Annual Global Healthcare Conference September 12, 2022 1:40 PM ET CorporateParticipants William Pao - Executive Vice President and Chief Development Officer Aamir Malik - Executive Vice President and Chief Business Innovation Officer ConferenceCall Participants Terence Flynn - Morgan Stanley Terence Flynn Okay, great. Thanks everybody for joining us. I'm Terence Flynn, the U.S. pharma analyst here at Morgan Stanley. We're very pleased to be hosting Pfizer today. Be ...

Pfizer Inc. (NYSE:PFE) Wells Fargo Healthcare Conference September 8, 2022 9:10 AM ET Company Participants David Denton - CFO & EVP Christopher Stevo - SVP & Chief IR Officer Conference Call Participants Mohit Bansal - Wells Fargo Securities Mohit Bansal Okay. Great. Thank you. Thank you, everyone, for joining us today. My name is Mohit Bansal. I'm one of the biopharma analysts here at Wells Fargo, and I have great pleasure to start with Dr. Dave Denton from Pfizer. David Denton I love it. Mohit Bansal And ...

Pfizer Inc. (NYSE:PFE) Citi's 17th Annual BioPharma Conference September 7, 2022 10:30 AM ET Company Representatives Mikael Dolsten - President, Head of R&D and Medical Chris Stevo - Senior Vice President, Chief Investor Relations Officer Conference Call Participants Andrew Baum - Citi Chris Stevo Alright, before Andrew and Mikael get started, I need to read a quick forward-looking statement. I'd like to point out that our discussion today may include forward-looking statements. Forward-looking information ...

Pfizer Inc. (NYSE:PFE) Q2 2022 Earnings Conference Call July 28, 2022 10:00 AM ET Company Participants Chris Stevo – Senior Vice President and Chief Investor Relations Officer Albert Bourla – Chairman and Chief Executive Officer Dave Denton – Chief Financial Officer Mikael Dolsten – President-Worldwide Research and Development and Medical Angela Hwang – Group President, Pfizer Biopharmaceuticals Group Aamir Malik – Chief Business and Innovation Officer William Pao – Chief Development Officer Conference Call ...

Pfizer Inc. (NYSE:PFE) Storebrand Conference: Invest in the Future Conference June 16, 2022 5:40 AM ET Company Participants Mikael Dolsten - Chief Scientific Officer and President, Worldwide Research, Development & Medical Question-and-Answer Session Q - Unidentified Analyst Take us back to the day, to the moment when you found out that the vaccine worked? Mikael Dolsten It was a very special moment. We were gathered, a small core team from the executive leadership of Pfizer and our CEO, Albert Bourla. And ...

Summary of Pfizer Inc. Conference Call Company Overview - **Company**: Pfizer Inc. (NYSE:PFE) - **Event**: Goldman Sachs 43rd Annual Global Healthcare Conference - **Date**: June 15, 2022 Key Points Leadership and R&D Focus - Mikael Dolsten, Chief Scientific Officer, emphasized the importance of maintaining high quality in R&D while improving speed and cost efficiency to deliver medicines to patients [6][9] - William Pao, EVP and Chief Development Officer, highlighted the need for execution and speed in product development, leveraging lessons learned from COVID-19 vaccine and treatment development [15][16] Revenue and Growth Strategy - Pfizer aims for a 6% compound annual growth rate (CAGR) through the end of the decade, focusing on both internal development and business development activities [8][10] - The company is targeting a loss of exclusivity (LOE) goal of $25 billion to maintain steady growth [10] COVID-19 Vaccine and Treatment Updates - Pfizer is preparing for the upcoming VRBPAC meeting to discuss the Omicron-adapted booster vaccine, with data expected to support a bivalent vaccine approach [19][20] - The company has a robust manufacturing capability to supply vaccines quickly, aiming to protect various age groups [20][22] - PAXLOVID has shown a 90% reduction in hospitalization and death among high-risk patients, with over 1.3 million prescriptions and a market share exceeding 90% [30] PAXLOVID Rebound Phenomenon - A 2% rebound rate was observed in patients treated with PAXLOVID, similar to a 1.6% rate in placebo patients, indicating that rebound may not be specific to the treatment [31][32] - No evidence of molecular resistance has been found, and the company is exploring extended dosing for immunocompromised patients [33][40] Pipeline Developments - Pfizer is optimistic about its mRNA flu vaccine, aiming for a differentiated product with higher immune response and better tolerability compared to current vaccines [44][45] - The RSV vaccine is positioned to be best-in-class, with a unique bivalent formulation and a focus on maternal immunization [47][48] Etrasimod and Other Pipeline Assets - Etrasimod has shown promising results in ulcerative colitis studies, with a 25% delta in clinical remission rates [52] - The drug's profile suggests potential for use in other indications without the need for titration, enhancing its attractiveness [55] CNS and Rare Diseases - Pfizer is strategically focusing on CNS and rare diseases, with ongoing programs in DMD and ALS, while also exploring opportunities in migraine treatments [69] Future Outlook - The company is committed to leveraging its R&D capabilities to address unmet medical needs and maintain a competitive edge in the pharmaceutical industry [11][12] Additional Insights - Pfizer's approach combines internal and external assets to enhance its product offerings and address market needs effectively [67] - The company is actively monitoring the evolving landscape of COVID-19 and its variants to adapt its strategies accordingly [27][28] This summary encapsulates the key discussions and strategic directions outlined during the conference call, reflecting Pfizer's commitment to innovation and growth in the healthcare sector.

Summary of Pfizer Inc. Conference Call Company Overview - **Company**: Pfizer Inc. (NYSE:PFE) - **Event**: Bernstein 38th Annual Strategic Decisions Conference - **Date**: June 01, 2022 Key Industry Insights COVID-19 Vaccine and Treatment - Pfizer is preparing for ongoing COVID-19 treatment usage, indicating that treatments will become the primary tool for managing the virus as social distancing measures relax [3][4][5] - The company acknowledges that the virus will continue to mutate and that compliance with vaccination may decline, leading to potential waves of COVID-19 with increased severity [4][5] - Current vaccination strategies may not ensure long-lasting immunity, as the virus does not create durable immune responses [4][5] - Pfizer is focusing on developing vaccines that align with consumer preferences and have longer durations of effectiveness [5] PAXLOVID Usage and Demand - PAXLOVID is currently more utilized in the U.S. than in Europe, with a reported increase in weekly treatments from 35,000 to 90,000 [11] - Approximately 60% of eligible individuals in the U.S. are receiving PAXLOVID, indicating a significant uptake compared to previous months [11] - Pfizer has contracts with various countries for PAXLOVID, with some European countries delaying supply to align with new variants [10][11] Resistance and Development of PAXLOVID - There is currently no evidence of resistance to PAXLOVID, and the company is monitoring this closely [16][17] - Pfizer is developing second-generation antiviral treatments as a precaution against potential resistance [17] Drug Development Innovations - PAXLOVID was developed using artificial intelligence and machine learning, significantly reducing the time from molecule design to testing [20][26] - Pfizer aims to apply these modern technologies across its entire portfolio, moving from drug discovery to drug design [23][26] Financial and Strategic Insights Diversification and Growth Profile - Pfizer's diversified portfolio includes eight products generating over $1 billion, which is viewed positively by investors [50] - The company emphasizes that a diversified asset base is more resilient than reliance on one or two major products [50] Reputation and Competitive Advantage - Pfizer's strong reputation has improved its ability to recruit talent and engage in strategic partnerships [51] - The company believes its brand name, capital flexibility, and operational capabilities provide a competitive edge [51] JAK Class and Immunology Strategy - Pfizer has invested heavily in the JAK class, developing multiple JAK inhibitors for different diseases to optimize efficacy [55][58] - The company is open to the idea of being a fast follower in the market, learning from competitors' successes [62] Regulatory and Market Challenges Antitrust Concerns - The Federal Trade Commission's increased scrutiny on pharmaceutical mergers and acquisitions may pose challenges for large companies like Pfizer [75][79] - Pfizer believes that acquiring smaller companies with promising molecules enhances competition rather than diminishes it [79] Drug Pricing and Markup Issues - The company acknowledges that drug pricing practices in hospitals can significantly impact patients and insurance companies, though it views this as less of a problem for the industry itself [82][84] Conclusion - Pfizer is navigating a complex landscape of COVID-19 management, innovative drug development, and regulatory scrutiny while maintaining a diversified portfolio that positions it for long-term growth and resilience in the pharmaceutical industry.

Good day, everyone, and welcome to Pfizer's first quarter 2022 earnings conference call. Today's call is being recorded. At this time, I would like to turn the call over to Chris Devo, Senior Vice President and Chief Investor Relations Officer. Please go ahead, sir. Thank you, operator. Good morning. Welcome to Pfizer's first quarter earnings call. I'm joined today by Dr. Albert Bourla, our Chairman and CEO, Frank D'Amelio, our CFO, and Michael Dolston, President of Worldwide Research and Development in Med ...